PAPER
Enantioselective Michael Additions
3833
1
3
(S)-2-[(R)-1-(2-Chlorophenyl)-2-nitroethyl]cyclohexanone18
(Table 3, Entry 11)
C NMR (75 MHz, CDCl ): d = 211.7, 133.4, 129.7, 129.5, 124.6,
3
1
24.4, 116.0, 115.7, 78.8, 52.4, 43.2, 42.7, 33.2, 28.4, 25.0.
HPLC: Chiralpak AD-H, i-PrOH–hexane (10:90), flow rate 0.5 mL/
(
S)-2-[(R)-1-(3,4-Dimethoxyphenyl)-2-nitroethyl]cyclo-
min, l = 254 nm; t
= 23.31 min, tmajor = 39.70 min; dr (syn/anti)
minor
19
hexanone (Table 3, Entry 7)
>99:1; ee = 95%.
25
[
a]D –28.4 (c 1.2, CHCl3).
HPLC: Chiralpak AS-H, i-PrOH–hexane (30:70), flow rate 1.0 mL/
= 12.94 min, tmajor = 24.49 min; dr (syn/anti)
1
H NMR (300 MHz, CDCl ): d = 7.39–7.36 (m, 1 H), 7.24–7.18 (m,
3
3 H), 4.90 (d, J = 1.2 Hz, 1 H), 4.88 (s, 1 H), 4.33–4.25 (dt, J = 6.6,
7.2, 9.9 Hz, 1 H), 2.96–2.87 (m, 1 H), 2.50–2.35 (m, 2 H), 2.14–2.06
(m, 1 H), 1.84–1.53 (m, 4 H), 1.39–1.26 (m, 1 H).
13
min, l = 254 nm; t
minor
>
99:1; ee >99%.
1
H NMR (400 MHz, CDCl ): d = 6.81 (d, J = 8.2 Hz, 1 H), 6.70–
C NMR (75 MHz, CDCl ): d = 211.6, 135.5, 134.5, 130.4, 129.5,
3
3
6
.66 (m, 2 H), 4.91 (dd, J = 7.8, 4.6 Hz, 1 H), 4.60 (dd, J = 9.9, 2.4
128.9, 127.4, 77.2, 51.7, 42.8, 41.0, 33.0, 28.5, 25.3.
Hz, 1 H), 3.87 (s, 6 H), 3.72–3.68 (m, 1 H), 2.66–2.64 (m, 1 H),
2
1
.49–2.45 (m, 1 H), 2.41–2.38 (m, 1 H), 2.07–2.04 (m, 1 H), 1.80–
.60 (m, 4 H), 1.27–1.23 (m, 1 H).
(S)-2-[(R)-1-(2-Bromophenyl)-2-nitroethyl]cyclohexanone5f
(Table 3, Entry 12)
1
3
HPLC: Chiralpak AD-H, i-PrOH–hexane (10:90), flow rate 1.0 mL/
min, l = 254 nm; tminor = 10.81 min, tmajor = 16.32 min; dr (syn/anti)
>99:1; ee = 98%.
C NMR (100 MHz, CDCl ): d = 212.2, 149.2, 148.6, 130.2, 120.5,
3
1
11.5, 79.1, 56.0, 52.7, 43.8, 42.6, 33.3, 28.5, 27.5, 25.1.
1
(
S)-2-[(R)-1-(Benzo[d][1,3]dioxol-5-yl)-2-nitroethyl]cyclo-
H NMR (300 MHz, CDCl ): d = 7.57 (d, J = 8.1 Hz, 1 H), 7.32–
3
5f
hexanone (Table 3, Entry 8)
7.21 (m, 2 H), 7.15–7.10 (m, 1 H), 4.90 (d, J = 8.1 Hz, 2 H), 4.32
(dd, J = 6.3, 6.6Hz, 1 H), 2.91–2.88 (m, 1 H), 2.45–2.34 (m, 2 H),
2
25
[
a]D –43.8 (c 1.5, CHCl3).
HPLC: Chiralpak AD-H, i-PrOH–hexane (10:90), flow rate 1.0 mL/
= 17.43 min, tmajor = 18.74 min; dr (syn/anti)
.12–2.08 (m, 1 H), 1.84–1.53 (m, 4 H), 1.40–1.20 (m, 1 H).
1
3
min, l = 254 nm; t
>
C NMR (75 MHz, CDCl ): d = 211.6, 137.2, 133.6, 129.0, 127.9,
minor
3
99:1; ee >99%.
77.3, 52.1, 43.0, 42.6, 41.9, 32.9, 28.5, 25.2.
1
H NMR (300 Hz, CDCl ): d = 6.75 (d, J = 7.8 Hz, 1 H), 6.66 (s, 2
3
S)-2-[(S)-1-(Furan-2-yl)-2-nitroethyl]cyclohexanone16 (Table
, Entry 13)
HPLC: Chiralpak AD-H, i-PrOH–hexane (10:90), flow rate 1.0 mL/
(
3
H), 6.64–6.58 (m, 2 H), 5.96 (s, 2 H), 4.92 (dd, J = 4.5, 12.3 Hz, 1
H), 4.56 (dd, J = 4.5, 9.9 Hz, 1 H), 3.67 (dt, J = 4.5, 9.9 Hz, 1 H),
2
1
.68–2.56 (m, 1 H), 2.51–2.33 (m, 2 H), 2.15–2.07 (m, 1 H), 1.83–
.61 (m, 4 H), 1.31–1.25 (m, 1 H).
min, l = 254 nm; tmajor = 10.47 min, tminor = 13.27 min; dr (syn/anti)
>99:1; ee = 91%.
1
3
C NMR (75 MHz, CDCl ): d = 211.7, 148.0, 147.1, 131.2, 121.6,
3
1
H NMR (300 Hz, CDCl ): d = 7.36 (d, J = 1.2 Hz, 1 H), 6.29 (dd,
3
1
08.5, 108.0, 101.2, 78.9, 52.5, 43.6, 42.6, 33.2, 28.3, 25.1.
J = 1.8, 3.3 Hz, 1 H), 6.16 (d, J = 3.3 Hz, 1 H), 4.81–4.62 (m, 2 H),
3.99 (dt, J = 4.8, 9.3 Hz, 1 H), 2.79–2.71 (m, 1 H), 2.51–2.32 (m, 2
H), 2.16–2.07 (m, 1 H), 1.92–1.56 (m, 4 H), 1.35–1.23 (m, 1 H).
13
S)-2-[(R)-1-(Naphthalen-1-yl)-2-nitroethyl]cyclohexanone5f
(
(
[
Table 3, Entry 9)
25
a]D –99.8 (c 1.1, CHCl3).
C NMR (75 MHz, CDCl ): d = 210.9, 150.8, 142.3, 110.3, 108.9,
3
7
6.6, 51.0, 42.5, 37.5, 32.4, 28.2, 25.0.
HPLC: Chiralpak AS-H, i-PrOH–hexane (30:70), flow rate 1.0 mL/
= 10.60 min, tmajor = 15.43 min; dr (syn/anti
min, l = 254 nm; t
minor
R)-Tetrahydro-3-[(R)-2-nitro-1-phenylethyl]pyran-4-one17
Table 3, Entry 14)
(
(
>
1
99:1; ee >99%.
H NMR (300 Hz, CDCl ): d = 8.17 (s, 1 H), 7.86 (d, J = 7.8 Hz, 1
3
HPLC: Chiralpak AS-H, i-PrOH–hexane (30:70), flow rate 1.0 mL/
= 14.10 min, tmajor = 17.69 min; dr (syn/anti)
H), 7.75 (d, J = 8.1 Hz, 1 H), 7.60–7.35 (m, 4 H), 5.06 (dd, J = 4.5,
min, l = 254 nm; t
minor
1
2
1
2.6 Hz, 1 H), 4.91–4.88 (m, 1 H), 4.76 (s, 1 H), 2.65 (br s, 1 H),
.45–2.38 (m, 2 H), 2.09–2.04 (m, 1 H), 1.69–1.47 (m, 4 H), 1.29–
.20 (m, 1 H).
>
99:1; ee = 96%.
1
H NMR (300 MHz, CDCl ): d = 7.39–7.27 (m, 3 H), 7.24–7.17 (m,
3
2
H), 4.78–4.62 (m, 2 H), 4.11–4.02 (m, 1 H), 3.87–3.75 (m, 2 H),
1
3
C NMR (75 MHz, CDCl ): d = 212.1, 134.5, 128.9, 128.1, 126.3,
3
3.70 (dd, J = 4.8, 11.7 Hz, 1 H), 3.29 (dd, J = 9.6, 11.4 Hz, 1 H),
1
25.7, 125.1, 123.5, 122.4, 78.6, 53.5, 42.7, 36.5, 33.1, 28.5, 25.1.
2
.93–2.85 (m, 1 H), 2.73–2.62 (m, 1 H), 2.58–2.49 (m, 1 H).
13C NMR (75 MHz, CDCl
): d = 209.3, 136.3, 129.2, 128.3, 128.0,
8.6, 54.7, 44.6, 43.5, 35.2, 31.7.
S)-2-[(R)-2-(Naphthalen-1-yl)-2-nitroethyl)cyclohexanone4d
3
(
(
[
7
Table 3, Entry 10)
25
a]D –69.2 (c 1.1, CHCl3).
R)-Tetrahydro-3-[(R)-2-nitro-1-phenylethyl]thiopyran-4-one17
Table 3, Entry 15)
(
(
HPLC: Chiralpak AD-H, i-PrOH–hexane (30:70), flow rate 1.0 mL/
min, l = 254 nm; tminor = 10.06 min, tmajor = 16.49 min; dr (syn/anti)
>
HPLC: Chiralpak AS-H, i-PrOH–hexane (30:70), flow rate 1.0 mL/
= 9.81 min, tmajor = 11.98 min; dr (syn/
99:1; ee >99%.
min, l = 254 nm; t
minor
1
anti) = 99:1; ee = 94%.
H NMR (300 MHz, CDCl ): d = 7.84–7.79 (m, 3 H), 7.63 (d,
3
J = 1.2 Hz, 1 H), 7.49–7.46 (m, 2 H), 7.30–7.26 (m, 1 H), 5.02 (dd,
J = 4.5, 12.6 Hz, 1 H), 4.73 (dd, J = 9.9, 12.3 Hz, 1 H), 3.99–3.92
(
H), 1.76–1.58 (m, 4 H), 1.29–1.25 (m, 1 H).
1
1
H NMR (300 MHz, CDCl ): d = 7.38–7.28 (m, 3 H), 7.23–7.17 (m,
3
2
H), 4.75 (dd, J = 4.8, 12.6 Hz, 1 H), 4.65 (dd, J = 9.6, 12.3 Hz, 1
H), 4.01 (dt, J = 4.5, 10.2 Hz, 1 H), 3.10–2.77 (m, 5 H), 2.62 (ddd,
J = 1.5, 4.2, 13.8 Hz, 1 H), 2.46 (dd, J = 9.6, 13.8 Hz, 1 H).
m, 1 H), 2.78–2.75 (m, 1 H), 2.50–2.47 (m, 2 H), 2.42–2.39 (m, 1
3
C NMR (75 MHz, CDCl ): d = 211.8, 135.1, 133.4, 132.8, 128.9,
13
3
C NMR (75 MHz, CDCl ): d = 208.6, 136.7, 129.4, 128.6, 127.9,
3
1
2
27.9, 127.7, 126.5, 126.2, 125.2, 78.8, 76.6, 52.5, 44.1, 42.8, 33.3,
8.5, 25.0.
7
8.8, 71.9, 69.3, 53.5, 43.0, 41.5.
Synthesis 2008, No. 23, 3828–3834 © Thieme Stuttgart · New York